11,162 Shares in Relay Therapeutics, Inc. $RLAY Bought by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC acquired a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,162 shares of the company’s stock, valued at approximately $39,000.

A number of other large investors have also recently bought and sold shares of RLAY. FNY Investment Advisers LLC boosted its stake in shares of Relay Therapeutics by 100.0% during the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $34,000 after acquiring an additional 5,000 shares in the last quarter. Private Capital Advisors Inc. boosted its position in Relay Therapeutics by 341.7% during the second quarter. Private Capital Advisors Inc. now owns 441,739 shares of the company’s stock worth $1,528,000 after purchasing an additional 341,739 shares during the period. CWM LLC boosted its position in Relay Therapeutics by 181.2% during the second quarter. CWM LLC now owns 56,993 shares of the company’s stock worth $197,000 after purchasing an additional 36,724 shares during the period. Vanguard Personalized Indexing Management LLC boosted its position in Relay Therapeutics by 86.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 25,792 shares of the company’s stock worth $89,000 after purchasing an additional 11,990 shares during the period. Finally, 111 Capital bought a new stake in Relay Therapeutics during the second quarter worth approximately $86,000. 96.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Guggenheim assumed coverage on shares of Relay Therapeutics in a report on Thursday, September 4th. They set a “buy” rating and a $15.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Tuesday, October 14th. Raymond James Financial decreased their price target on shares of Relay Therapeutics from $29.00 to $19.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. Finally, HC Wainwright decreased their target price on Relay Therapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Relay Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Relay Therapeutics Stock Performance

NASDAQ RLAY opened at $7.14 on Monday. The firm has a 50-day simple moving average of $5.25 and a 200 day simple moving average of $3.99. Relay Therapeutics, Inc. has a twelve month low of $1.77 and a twelve month high of $7.64. The stock has a market cap of $1.23 billion, a PE ratio of -3.66 and a beta of 1.75.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.08. The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.07 million. Research analysts forecast that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Donald A. Bergstrom sold 30,897 shares of the firm’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $7.29, for a total value of $225,239.13. Following the completion of the transaction, the insider directly owned 521,823 shares of the company’s stock, valued at $3,804,089.67. This trade represents a 5.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peter Rahmer sold 21,394 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $7.50, for a total value of $160,455.00. Following the completion of the transaction, the insider directly owned 337,469 shares of the company’s stock, valued at approximately $2,531,017.50. This trade represents a 5.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 93,090 shares of company stock valued at $683,119 over the last ninety days. 4.32% of the stock is owned by company insiders.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.